Main inclusion criteria include:~* Patient with clinical diagnosis of Alzheimer's disease based on the
International Working Group criteria according to the European Guideline on the clinical investigation of
medicines for the treatment of Alzheimer's disease (CPMP/EWP/553/95 Rev.2 - 2018) at screening visit~* Patient
with MMSE ≥ 14 and ≤ 25 at screening visit and baseline visit~* Patient with Alzheimer's disease biomarker
profile at screening visit~* Patients treated for a minimum of 6 months with a stable dose of cholinesterase
inhibitors (donepezil, rivastigmine or galantamine) at baseline visit, and/or a stable dose of memantine for a
minimum of 6 months at baseline visit, with no changes foreseen in therapy throughout the study~* If receiving
a supplement for cognition (eg, gingko biloba, omega-3 polyunsaturated fatty acid, vitamin E, curcumin,
souvenaid) must be taking a stable dose for at least 4 months prior to screening visit~
